Fresenius Kabi and ASPEN partner for an expert interview series on omega-3 fatty acid containing parenteral nutrition
BAD HOMBURG, Germany, Nov. 23, 2020 /PRNewswire/ -- Evidence indicates that omega-3 (ω-3) fatty acid containing parenteral nutrition (PN) improves clinical outcomes compared with standard PN in adult patients,1 underlining its role in today's hospitals and clinics. To support continuous health care professional (HCP) education on omega-3 fatty acids in clinical nutrition, the American Society for Parenteral and Enteral Nutrition (ASPEN) has partnered with Fresenius Kabi to create the Omega-3 Fatty Acids Key Expert Interview Series, which includes five interviews addressing important aspects of omega-3 fatty acids impacting patient care.
The interview series features the following experts and topics: Mette M. Berger, MD, PhD (Role and Mechanism of Action of omega-3 Fatty Acids); Robert G. Martindale, MD, PhD (Guideline Recommendations and Use in Surgical Patients); Martin D. Rosenthal, MD (Use in the Chronic Critical Care Patient); Lorenzo Pradelli, MD (Cost Effectiveness of omega-3 Fatty Acids); and Manpreet S Mundi, MD (Omega-3 Fatty Acids in Long-term Intestinal Failure Patients). The esteemed experts were interviewed by Jay Mirtallo, MS, RPh, BCNSP, FASPEN, FASHP, who is well published in the area of intravenous lipids.
This short video interview series is available at this link.
Clinicians can also watch previous ASPEN webinars on omega-3 fatty acids:
- Expert Consensus on Omega-3 Fatty Acids in Parenteral Nutrition: Continuum of Care – from Hospital to Home Care
- Expert Consensus on Omega-3 Fatty Acids in Parenteral Nutrition: Focus on Critical Care and Major Surgery
The digital interviews and past webinars are supported by global clinical nutrition leader, Fresenius Kabi. The supplement of the 2020 Journal of Parenteral and Enteral Nutrition Lipids in Parenteral Nutrition: Translating Guidelines into Clinical Practice was also developed on the topic of omega-3 fatty acids with support from Fresenius Kabi.
- Pradelli L, Mayer K, Klek S et al. ω-3 Fatty-Acid Enriched Parenteral Nutrition in Hospitalized Patients: Systematic Review With Meta-Analysis and Trial Sequential Analysis. JPEN J Parenter Enteral Nutr. 2019.
About Fresenius Kabi
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients. Fresenius Kabi's product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems. In the field of biosimilars, Fresenius Kabi develops products with a focus on oncology and autoimmune diseases.
With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
For more information, please visit www.fresenius-kabi.com.
The American Society for Parenteral and Enteral Nutrition (ASPEN) is dedicated to improving patient care by advancing the science and practice of nutrition support therapy and metabolism. Founded in 1976, ASPEN is an interdisciplinary organization whose members are involved in the provision of clinical nutrition therapies, including parenteral and enteral nutrition. With more than 6,500 members from around the world, ASPEN is a community of dietitians, nurses, nurse practitioners, pharmacists, physicians, scientists, students and other health professionals from every facet of nutrition support clinical practice, research and education. For more information about ASPEN, please visit www.nutritioncare.org.
For press inquiries, please contact:
Am Sandtorkai 50, 20457 Hamburg, Germany
T: +49 (0)69 509546339
SOURCE Fresenius Kabi Deutschland GmbH
- PR Newswire Asia release